Connect with us

Business

Third member of prestigious FDA panel resigns over approval of Biogen’s Alzheimer’s drug – CNBC

A third member of a key FDA panel has resigned over the agency’s controversial decision to approve Biogen’s new Alzheimer’s drug,…

Published

on

Article feature image
ADVERTISEMENT

A third member of a key Food and Drug Administration advisory panel has resigned over the agency’s controversial decision to approve Biogen’s new Alzheimer’s drug, Aduhelm, CNBC has learned.
Dr. Aaron Kesselheim, a professor of medicine at Harvard Medical…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

Article feature image
New Tesla Model S Long Range Gets Official EPA Range Rating – InsideEVs
Article feature image
Summer vacation? Amtrak Rail Pass offers 10 trips for $299 with passes available through June 22 – USA TODAY
Article feature image
Chobani Taps Goldman Sachs, Bank of America for 2021 IPO – Yahoo Finance